Jazz Pharmaceuticals plc
JAZZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,126,107 | $1,045,712 | $897,841 | $1,088,173 |
| % Growth | 7.7% | 16.5% | -17.5% | – |
| Cost of Goods Sold | $257,760 | $116,268 | $104,620 | $128,713 |
| Gross Profit | $868,347 | $929,444 | $793,221 | $959,460 |
| % Margin | 77.1% | 88.9% | 88.3% | 88.2% |
| R&D Expenses | $240,703 | $189,972 | $180,652 | $240,500 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $530,647 | $358,399 | $514,013 | $369,287 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $39,488 | $1,067,465 | $154,448 | $158,903 |
| Operating Expenses | $810,838 | $1,615,836 | $849,113 | $768,690 |
| Operating Income | $57,509 | -$686,392 | -$55,892 | $190,770 |
| % Margin | 5.1% | -65.6% | -6.2% | 17.5% |
| Other Income/Exp. Net | -$48,474 | -$49,162 | -$54,461 | -$57,567 |
| Pre-Tax Income | $9,035 | -$735,554 | -$110,353 | $133,203 |
| Tax Expense | -$242,424 | -$17,084 | -$17,812 | -$57,912 |
| Net Income | $251,412 | -$718,470 | -$92,541 | $191,115 |
| % Margin | 22.3% | -68.7% | -10.3% | 17.6% |
| EPS | 4.14 | -11.74 | -1.52 | 3.16 |
| % Growth | 135.3% | -672.4% | -148.1% | – |
| EPS Diluted | 4.08 | -11.74 | -1.52 | 3.11 |
| Weighted Avg Shares Out | 60,696 | 61,194 | 60,979 | 60,538 |
| Weighted Avg Shares Out Dil | 61,606 | 61,194 | 60,979 | 61,503 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $48,576 | $47,363 | $53,706 | $51,256 |
| Depreciation & Amortization | $178,246 | $174,009 | $164,873 | $168,417 |
| EBITDA | $235,857 | -$514,182 | $138,861 | $396,981 |
| % Margin | 20.9% | -49.2% | 15.5% | 36.5% |